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B6.Nba2 mice spontaneously develop a lupus-like disease characterized by elevated
levels of serum anti-nuclear autoantibody (ANA) immune complexes and constitutive
type I interferon (IFNα) production. During disease progression, both plasmacytoid
dendritic cells (pDCs) and antibody secreting plasma cells accumulate in spleens of
B6.Nba2 mice. Indoleamine 2,3-dioxygenase (IDO) has been suggested to play a role
in several autoimmune diseases including in the MRL/lpr model of mouse lupus-like
disease; however, it remains unknown if IDO is involved in disease development and/or
progression in other spontaneous models. We show here that IDO1 protein and total
IDO enzymatic activity are significantly elevated in lupus-prone B6.Nba2 mice relative to
B6 controls. IDO1 expression was restricted to PCs and SignR1+ macrophages in both
strains, while significantly increased in B6.Nba2-derived SiglecH+ (SigH+) pDCs. Despite
this unique expression pattern, neither pharmacologic inhibition of total IDO nor IDO1
gene ablation altered serum autoantibody levels, splenic immune cell activation pattern,
or renal inflammation in B6.Nba2 mice. Interestingly, IDO pharmacologic inhibition, but
not IDO1 deficiency, resulted in diminished complement factor C’3 fixation to kidney
glomeruli, suggesting a possible therapeutic benefit of IDO inhibition in SLE patients
with renal involvement.
Keywords: antibodies, autoimmunity, dendritic cells, rodent, immunization, systemic lupus erythematosus,
transgenic/knockout mice
INTRODUCTION
Oxidative tryptophan (Trp) degradation is driven via the kynurenine pathway by one of three rate
limiting enzymes: tryptophan 2,3-dioxygenase, indoleamine 2,3-dioxygenase (IDO)-1, or IDO2
(1). Induction of IDO activity depletes the local environment of Trp, triggering the general
amino acid control non-depressible 2 (GCN2) stress pathway preventing T cell proliferation
and inducing anergy (2–5). Concomitantly, downstream metabolites of IDO enzymatic activity
such as 3-hydroxyanthranilic acid (3-HAA) and quinolinic acid (QA) have been shown to
induce the generation, and support the maintenance, of regulatory T cells (Tregs) (6, 7).
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Thus, IDO (−1 and −2) have been suggested to mediate
immune tolerance under various conditions such as chronic
inflammation, cancer, and autoimmunity (8–11). IDO1 and
IDO2 molecules have been suggested to be expressed by
plasmacytoid dendritic cells (pDCs) (CD19+ and SigH+),
macrophages (SignR1+), myeloid-derived suppressor cells
(MDSCs), and lately also B cells and plasma cells (12–23). In
addition to a role in T cell differentiation and activity, recent
studies have suggested that IDO1 and/or IDO2 may also control
humoral immunity via B-cell intrinsic mechanisms (17, 24).
Given this potent immunomodulatory function, IDO
has been studied in patients with autoimmunity and in a
variety of autoimmune mouse models. These studies found
that total IDO is elevated in patients with rheumatoid
arthritis (RA) (25) and systemic lupus erythematosus (SLE)
(26–28). Similarly, IDO1 is overexpressed in spleens from
MRLlpr lupus-prone mice (18). Interestingly, inhibition of
total IDO enzymatic activity via treatment with 1-D-MT,
a tryptophan analog, accelerated the development of anti-
nuclear autoantibodies (ANA) and glomerulonephritis (GN)
in MRLlpr lupus-prone mice (18). Likewise, in a model of
experimental autoimmune encephalomyelitis (EAE), IDO1-
deficiency exacerbated disease development by reducing
numbers of Tregs, while treatment with the Treg-inducing
metabolite 3-HAA ameliorated disease development (6).
Similarly, collagen-induced arthritis and TNBS-induced colitis
models also showed exacerbated disease development after
1-MT treatment (29, 30) and it has been suggested that
IDO1-deficient mice responded stronger to T-independent
antigen immunization than wild type non-autoimmune mice
(17). Oppositely however, IDO1-deficiency had no effect
on the spontaneous development of experimental RA in
transgenic KRN mice, although treatment with 1-D/L-MT
or IDO2-deficiency resulted in less severe disease (31, 32).
Thus, IDO1 and IDO2 may play different roles in different
disease models.
B6.Nba2 mice develop a lupus-like disease evident by the
presence of hypergammaglobulinemia, elevated serum ANA,
increased type I interferon (IFNα) levels, splenomegaly, GN,
and IgG-immune complex (IgG-IC) deposition in the kidneys
(33–37). Already at 2 months of age, and increasing thereafter,
B6.Nba2 mice present with hyperactivated B cells and elevated
levels of plasma cells and pDCs as compared with age- and sex-
matched B6 mice (36, 37). Given the potential role of IDO in
autoimmunity and the accumulation of these potential IDO-
producing cell subsets, we investigated the role of IDO in lupus-
like disease development of progression in B6.Nba2 mice. We
show here that the levels of IDO1 protein and IDO enzymatic
activity were in fact significantly elevated in spleens of B6.Nba2
mice. In agreement with previous literature, IDO1 protein was
measurable in SigH+ pDCs, SignR1+ macrophages as well as
plasma cells, but not in T cells or B cells. Surprisingly, however,
neither IDO1-deficiency nor pharmacological inhibition of
IDO enzymatic activity had any effect on disease parameters
including serum ANA, splenomegaly, hyperactive lymphocytes,
GN, and IgG-IC deposition. On the other hand, pharmacological
inhibition alone resulted in diminished complement factor
C’3 fixation to kidney glomeruli. Dual manipulation (1-D-
MT treatment of IDO1−/− B6.Nba2 mice) had no effect on
spontaneous lupus-like disease development, despite elevating
the humoral immune response to T-dependent antigen. Thus, we
conclude that IDO suppresses humoral immunity to exogenous
antigen in lupus-prone B6.Nba2 mice but fails to affect lupus-
like disease development. Yet further studies will be needed to
determine whether IDO inhibition could be beneficial for SLE
patients with renal involvement.
MATERIALS AND METHODS
Mice
C57BL/6J (B6) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). B6.Nba2 mice were transferred
from the University of Colorado at Denver Health Sciences
Center and are currently bred in our facility. B6.Nba2 IDO1-
deficient mice (B6.Nba2.IDO1−/−) were generated in house
by backcrossing B6.IDO1−/− (generously provided by Dr.
Ram Nagaraj of Case Western Reserve University) onto the
B6.Nba2 background.Marker-assisted polymerase chain reaction
technique was employed and genotypes were ascertained
to ensure that the complete Nba2 region was maintained,
as previously described (36, 37). Genotyping for Ido1 was
performed according to the protocol by Jackson Laboratories.
All mice were maintained in the Biological Research Unit at the
Lerner Research Institute, in accordance with Cleveland Clinic
Foundation Animal Research Committee guidelines. Animal
studies were approved by the Institutional Animal Care and Use
Committee of the Lerner Research Institute of the Cleveland
Clinic Foundation and conducted in compliance with guidelines
issued by the National Institutes of Health.
Systemic IDO Inhibition With 1-D-MT
Systemic inhibition of total IDO was achieved using 1-D-MT, as
described (38). Briefly, mice were treated with 2 mg/mL 1-D-MT
(in 8mM NaOH, pH 7.0 ± 0.2), in the drinking water for 4–
20 consecutive weeks, beginning at 8–12 weeks of age. Control
mice were given sham water (8mMNaOH, pH 7.0± 0.2). Water
bottles were kept in the dark and new water was supplied at
least weekly.
Flow Cytometry
Splenic single cell suspensions were prepared by gently separating
single cells between the frosted areas of two microscope
slides. Red blood cells were lysed using 1x ACK buffer
(0.15M NH4Cl, 0.01M KHCO3, 0.1mM EDTA). Cells were
stained for detection of surface and intracellular antigens
using antibodies specific to B220, CD3, CD4, CD5, CD8,
CD11b, CD11c, CD19, CD21/35, CD22, CD23, CD25, CD38,
CD40, CD44, CD62L, CD69, CD86, CD93 (AA4.1 clone),
CD115, CD138, F4/80, Foxp3, GL-7, Gr1, ICOS, IgD, IgM,
MHCII, PD-1, PDCA-1, Siglec-H, (eBiosciences Inc, CA),
MOMA-1 (Abcam, Cambridge, MA), CXCR5, Ly6-G (BD
Biosciences, CA), SignR-1 (AbD Serotec, NC). All samples were
treated with unlabeled anti-CD16/32 antibodies to reduce Fc-
receptor dependent non-specific antibody binding. Analyses
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of Foxp3 expressing cells were performed by preparing the
samples for intracellular staining using the manufacturer’s
protocol (Foxp3/Transcription Factor Staining Buffer Set,
eBiosciences). Non-specific, fluorescently-conjugated rat IgG2a
antibody (eBiosciences) was used as a control. Samples were run
on a FACS Calibur (BD Biosciences, San Jose, CA) and data
analysis was performed using FlowJoTM (Tree Star Inc., OR)
version 9.8.2. Live cells were determined based on forward and
side scatter properties; individual cell subsets were determined
by marker positivity, as indicated under each population name
in Table 1.
Western Blotting
Western blot was performed using total splenocyte lysates. A
single cell suspension was prepared from total spleen samples,
red blood cells were lysed, and remaining cells were resuspended
in Cell Lysis Buffer (Cell Signaling) containing 10% PhosSTOP
(Roche Applied Science). Lysates were denatured by boiling for
5min in Laemli sample buffer (60mMTris-HCl, pH 6.8, 2% SDS,
10% glycerol, 0.01% bromophenol blue, β-mercaptoethanol) and
15 µg of protein was loaded onto a 1.0 mm-thick 12% SDS-
PAGE gel. Gel proteins were transblotted onto nitrocellulose
membranes (0.45µm; Amersham Biosciences, Germany). The
membranes were blocked with phosphate buffered saline (PBS:
137mMNaCl, 2.7mMKCl, 10mMNa2HPO4, 1.8mMKH2PO4;
pH 7.4) containing 0.05% Tween-20 (PBST) and 2% non-
fat dry milk for 1 h at room temperature. Membranes were
incubated overnight at 4◦C in PBST containing 2% non-
fat dry milk with rabbit polyclonal IDO-specific antibody
(1:1,000, US Biological, MA). Membranes were washed in
PBST, incubated with horseradish peroxidase-conjugated anti-
rabbit IgG (1:4,000, Santa Cruz Biotechnology, TX) for 1 h at
room temperature, and washed again, before being developed
using Amersham ECL Western Blotting Detection Reagents
(GE Healthcare, Buckinghamshire, UK). Bands were detected
after exposure to Amersham Hyperfilm ECL high performance
chemiluminescence film (GE Healthcare) and quantified by
densitometry using ImageJ software (version 1.42q, NIH). After
quantification of IDO bands, gels were stripped in stripping
buffer (2.5mM Tris-HCl, pH 6.7, 100mM β-mercaptoethanol,
2% SDS) and levels of actin were determined as above using goat
polyclonal anti-Actin(C-11): sc-1615 (at 0.2 ug/mL; Santa Cruz
Biotechnology, TX). Results are expressed as ratios of intensity of
IDO1 to β-Actin internal standard.
TABLE 1 | Splenic cellular composition in 12 week old B6, B6.Nba2, and IDO-manipulated B6.Nba2 mice.
B6a B6.Nba2b B6.Nba2.IDO1–/–c B6.Nba2+ 1-D-MTd B6.Nba2.IDO1–/–+ 1-D-MTe
Total splenocytes in millions 75 ± 8.6f 130 ± 15.6* 113 ± 11.8* 100 ± 8.16(*) 117 ± 23.1
DENDRITIC CELLS (%)g
cDCs 0.8% ± 0.02 1.1% ± 0.05** 1.1% ± 0.17 0.9% ± 0.09 0.9% ± 0.08
pDCs (all) 0.8% ± 0.01 1.4% ± 0.17** 1.3% ± 0.14* 1.1% ± 0.23 1.1% ± 0.23
CD19+ pDCs 0.4% ± 0.05 0.9% ± 0.19* 1.1% ± 0.13* 0.7% ± 0.19 0.9% ± 0.23(*)
SiglecH+ pDCs 0.3% ± 0.04 0.2% ± 0.02 0.2% ± 0.02 0.2% ± 0.01 0.2% ± 0.02
T Cells (%)
CD8+(all) 14.1% ± 0.49 11.8% ± 0.62* 10.5% ± 1.40(*) 13.0% ± 0.41 11.3% ± 1.08(*)
CD4+(all) 22.4% ± 1.83 22.2% ± 1.92 18.7% ± 1.99 22.7% ± 1.68 18.7% ± 1.99
Foxp3+CD4+Treg 1.1% ± 0.21 1.5% ± 0.13 1.3% ± 0.10 1.4% ± 0.14 1.3% ± 0.05
Naïve CD4+CD62LhiCD44low 15.9% ± 1.2 10.7% ± 1.44* 8.8% ± 2.05* 12.8% ± 1.49 8.6% ± 1.62*
Eff-mem CD4+CD62LlowCD44hi 2.8% ± 0.17 6.1% ± 0.63** 6.0% ± 0.40** 4.7% ± 0.40** 5.8% ± 0.59*
CD69+CD4+ 1.6% ± 0.16 2.9% ± 0.38* 2.8% ± 0.33* 2.2% ± 0.21(*) 2.6% ± 0.21*
MYELOID CELLS (%)
Gr1+CD11b+ 2.9% ± 0.41 2.6% ± 0.26 5.3% ± 1.83 2.6% ± 0.33 2.7% ± 0.59
F4/80+CD11b+ 1.2% ± 0.10 0.6% ± 0.07** 0.6% ± 0.25 0.5% ± 0.05** 0.5% ± 0.06**
SignR1+MΦ 0.5% ± 0.01 0.3% ± 0.03*** 0.3% ± 0.06* 0.3% ± 0.04* 0.2% ± 0.01*** (#)
B Cells (%)
B cells (all) 48.1% ± 3.58 49.4% ± 2.64 49.5% ± 2.86 49.9% ± 2.53 53.1% ± 2.58
CD69+B220+ 0.1% ± 0.02 0.2% ± 0.03* 0.2% ± 0.01* 0.2% ± 0.01 0.2% ± 0.03
GC B cells 0.5% ± 0.08 1.9% ± 0.29** 1.5% ± 0.10** 1.5% ± 0.30* 1.4% ± 0.19*
CD138+B220low plasma cells 0.1% ± 0.002 0.6% ± 0.13** 1.0% ± 0.16* 0.5% ± 0.12** 0.5% ± 0.11*
an = 3;
bn = 8;
cn = 4;
dn = 7;
en = 4;
fAVG ± SEM, numbers expressed in millions.
gAVG ± SEM, numbers represent % of total splenocytes. (*) p = 0.05-0.09. *p < 0.05; **p < 0.01; ***p < 0.001, vs. B6. (#) p = 0.05–0.09 vs. B6.Nba2.
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IDO Enzymatic Activity Assay
Detection of total IDO enzymatic activity was performed as
previously described (39, 40). Briefly, spleen tissue was flash
frozen on dry ice and kept at −80◦C until further processing.
Tissues were then homogenized with a Polytron homogenizer
(Kinematica, Lucerne, Switzerland) in 1.5x volume of ice-cold
buffer (0.14M KCl, 20mM potassium phosphate buffer, pH
7.0). Homogenized samples were centrifuged for 10min at 7,000
× g and 4◦C. Aliquots of supernatant were taken for IDO
enzymatic activity measurement and mixed 1:1 in substrate
solution (100mM potassium phosphate buffer, pH 6.5; 50µM
methylene blue; 20 µg catalase; 50mM ascorbate; 0.4mM L-Trp)
in a total volume 100 µL. Reaction mixture was incubated at
37◦C, then acidified with 3% perchloric acid and centrifuged as
before. The concentrations of enzymatic products were measured
by HPLC. Enzyme activity is expressed as product content per
hour per gram of tissue protein.
Immunization
On day 0, mice were immunized intraperitoneally with 20 µg (4-
hydroxy-3-nitrophenylacetyl)27 conjugated chicken γ-globulin
(NP27-CGG) in CFA (Sigma-Aldrich, St. Louis, MO) in a total
volume of 200 µl per mouse. Serum samples were collected on
days -1, 7, 14, 21, and 28 by tail-vein bleeding. At day 28, all mice
were sacrificed and splenic cell populations were determined
by flow cytometry (see above). Treatment with 1-D-MT was
initiated at the time of immunization andmaintained throughout
the study.
Measurement of Serum Antibodies by
ELISA
Murine anti-chromatin-IgG, anti-histone-IgG, total IgG, and
total IgM antibodies were measured as previously described (33).
Sera were diluted in serum diluent (5 mg/ml bovine γ-globulin,
5% gelatin, 0.05% Tween in PBS) at 1:100,000 for determination
of total IgG and IgM levels, and at 1:300 for antigen-
specific antinuclear antibodies. Anti-NP specific antibodies were
determined by ELISA as previously described (41), at a dilution
of 1:10,000. Horse-radish peroxidase conjugated secondary
antibodies recognizing mouse IgG, IgG1, or IgG2a heavy chains
(Southern Biotech, AL) were used at 1:2,000, 1:2,000, and 1:1,000
dilutions, respectively. Colorimetric readings were obtained
using a Victor 3 plate reader (Perkin Elmer, Waltham, MA).
Immunofluorescence Staining
Kidney samples were embedded in Tissue-Tek optimal cutting
temperature compound (Sakura) and snap-frozen. Sections
(5µm) were air-dried, fixed with cold acetone, and washed
in PBS buffer. To prevent non-specific binding, sections were
blocked with anti-mouse CD16/CD32 (1:200, eBioscience) in
10% non-immune goat serum (Invitrogen). Sections were stained
with Tx Red-conjugated anti-mouse IgG2b (1:500, Southern
Biotech) and FITC-conjugated goat anti-mouse C3 (1:500, ICL).
Sections were then washed and mounted with 70% glycerol.
Image processing and analysis was performed on the BZ-X700
all-in-one fluorescence microscope (Keyence, Osaka, Japan).
Statistical Analyses
Statistical differences between cell populations and protein levels
of IDO1 were calculated using the Student’s unpaired t-test
(with Welch’s correction for cell populations). Differences in
longitudinal serum antibody data were determined using two-
way ANOVA test. For single time point analysis of serum
antibody levels, differences were calculated using the Student’s
unpaired t-test with Welch’s correction. For all analyses, p< 0.05
was considered statistically significant.
RESULTS
IDO1 Is Elevated in B6.Nba2 Lupus-Prone
Mice
Abnormal levels of IDO have been reported in both SLE patients
and mouse models of lupus (18, 28). To establish if IDO was
dysregulated in lupus-prone B6.Nba2 mice, we tested basal levels
of IDO1 and IDO2 in spleens from unmanipulated female
B6.Nba2 strains and control age- and sex-matched B6 mice.
IDO1 levels were significantly elevated in spleens of female
B6.Nba2 mice (Figures 1A,B). We were unable to detect IDO2
protein in total spleen samples from these mice as previously
described (42) (data not shown). Since levels of IDO1 protein
are not necessarily a direct indication of total IDO enzymatic
activity, quick-frozen spleen samples were subsequently tested
for total IDO enzymatic activity in an in vitro tryptophan
(Trp) catabolism assay (40). Enzymatic Trp degrading activity
was significantly elevated in female B6.Nba2 mice as compared
with age- and sex-matched B6 control mice (Figure 1C). In
conclusion, both levels of IDO1 and total IDO enzymatic
activity were found to be elevated in spleens from lupus-prone
B6.Nba2 mice.
IDO1 Deficiency and Total IDO Enzymatic
Inhibition Fail to Affect ANA Levels in
B6.Nba2 Mice
Previously, IDO-dependent Trp metabolism has been
shown to play a role in autoimmune disease etiology
(24, 26, 28). Given that IDO1 is both elevated and active
in B6.Nba2 mice, we investigated if expression of IDO1
and/or total IDO enzymatic activity affected the production of
autoantibodies in these mice. Cohorts of B6.Nba2.IDO1−/−
and B6.Nba2.IDO1+/+ littermates (Figure 2A) were treated
with 1-D-MT or sham-treated and followed longitudinally
until 24 weeks of age for the development of hyper IgM
syndrome, hypergammaglobulinemia, and elevated serum
ANA levels as previously described (34, 36). At the time of
harvest, spleens were isolated and weighed for detection of
splenomegaly. There was no effect of IDO1-deficiency or
total IDO enzymatic inhibition on spleen size (Figure 2B).
Serum total IgM or IgG antibody levels were neither
significantly nor consistently affected by IDO1 deficiency
and/or 1-D-MT treatment at any time point (shown are
data from 24 week old mice; Figures 2C–G). Although
B6.Nba2 mice treated with 1-D-MT showed statistically
significantly lower levels of anti-chromatin IgG than
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FIGURE 1 | IDO1 is elevated in disease-prone B6.Nba2 mice. Western blot analysis of splenic IDO1 levels in unmanipulated, 16 week old female B6 and B6.Nba2
mice. (A) One sample representative is shown for B6 and B6.Nba2. (B) Quantification of IDO1 western blot analyses [B6: n = 6; B6.Nba2: n = 3]. Each bar shows
Mean ± SEM. Student’s unpaired t-test: ***p < 0.001. (C) Analysis of IDO enzymatic activity in spleens of B6 and B6.Nba2. Each symbol represents data from an
individual mouse. Shown is Mean ± SEM. Student’s unpaired t-test: p < 0.05.
FIGURE 2 | IDO1-deficiency and/or 1-D-MT treatment do not affect the development of splenomegaly and autoantibody production in B6.Nba2 mice. IDO1-deficient
and –sufficient B6.Nba2 mice were bred (A) and treated with PBS or 1-D-MT in the drinking water from 8 to 24 weeks of age. At 24 weeks of age, mice were harvested
and spleen weights were recorded (B). Serum was obtained monthly and evaluated for total IgM (C), total IgG (D), anti-dsDNA IgG (E), anti-chromatin IgG (F), and
anti-histone IgG (G). Shown are data from 24 week old mice. Each symbol represents one mouse. *p < 0.05, Student’s unpaired t-test with Welch’s correction.
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untreated, IDO1-sufficient B6.Nba2 mice (Figure 2F), this
observation was not consistent across other autoantibody
specificities (Figures 2E,G).
Disease progression in B6.Nba2 mice is prominent from 8 to
16 weeks of age where splenic cellular differences first become
measurable (35–37). In order to adequately determine an effect
of IDO manipulation on early differences in autoantibody levels,
we repeated the above experiment following mice from 8 to 16
weeks of age. Consistent with data from 24 week old mice, there
were no changes in serum ANA levels in 12 week old mice after 4
weeks of IDO manipulation (Supplemental Figure 1).
Manipulation of IDO Does Not Affect
Immune Cell Abnormalities in B6.Nba2
Mice
Young B6.Nba2 mice display a number of characteristic immune
cell abnormalities (35–37). We analyzed spleens from 12 week
old B6.Nba2, IDO-manipulated B6.Nba2, and control non-
autoimmune B6 mice for the presence and activation status
of a number of immune cells involved in lupus pathogenesis.
In correlation with previous data, unmanipulated B6.Nba2
mice had significantly elevated numbers of total splenocytes
as compared with the B6 control strain (Table 1, top row; p
< 0.05). The percentage of spleen cell subsets and the total
number of cells within each subset present in spleens are
presented in Table 1 and Supplemental Table 1, respectively.
Overall, the percentages of total T cells and total B cells were
not significantly different between B6 and B6.Nba2 mice at
this age, except for a small reduction in the percentage of
total CD8+ T cells in B6.Nba2 mice (p < 0.05; Table 1). In
contrast, the percentages and numbers of conventional dendritic
cells (cDCs) and plasmacytoid DCs (pDCs) were elevated in
unmanipulated B6.Nba2 and IDO1−/− B6.Nba2 mice (Table 1,
p < 0.05–0.01). The increase in total pDCs in both strains was
mainly due to an increase in the CD19+ pDC subpopulation
(p < 0.05 compared with B6), while there were no significant
differences in the percentages of SigH+ pDCs between any of the
strains. Consistent with a disease-prone phenotype and previous
findings (35, 37), we also identified an increased presence of
activated lymphocytes (CD69+ T and B cells), a significant
shift in the ratio between naïve and effector-memory CD4+
T cells in B6 vs. B6.Nba2, and an increase in the percentage
of germinal center (GC) B cells and plasma cells, (p < 0.001,
Table 1 and data not shown). Similarly, the percentages and
numbers of CD69+ T and B cells were significantly increased
in IDO−/− B6.Nba2 mice, while only the percentage of CD69+
T cells was significantly elevated in 1-D-MT treated mice.
The percentages of germinal center (GC) B cells and plasma
cells were elevated in all B6.Nba2 mice regardless of the
IDO status (p < 0.05–0.01; Table 1 and Supplemental Table 1).
This pattern was further supported by the lack of statistically
significant differences between unmanipulated B6.Nba2 and
any of the IDO-manipulated groups. The observation was
not an effect of the young age of these mice, as similar
data were obtained from 24 to 28 week old mice (data not
shown). Finally, the percentages, but not numbers, of F4/80+
macrophages and SignR1+ MZ macrophages were reduced
in all B6.Nba2 mice (p < 0.05–0.001), while there were no
differences in the percentages and numbers of Gr1+CD11b+
myeloid cells.
Manipulation of IDO Enzymatic Activity in
B6.Nba2 Mice Does Not Affect Renal
Inflammation but Diminishes Complement
Fixation in Kidney Glomeruli
Evidence from us and others suggests that autoantibody levels
and renal disease may not always correspond in animal models
of lupus (33, 43, 44). We therefore determined the presence
of GN, mesangial proliferation, IgG-, and IgM-IC deposition
and subsequent complement fixation to kidney glomeruli in
B6.Nba2, B6.Nba2 treated with 1-D-MT, B6.Nba2.IDO1−/−,
and B6.Nba2.IDO1−/− treated with 1-D-MT. Inflammation of
kidneys from 12 to 24 week old mice was determined based
on hematoxylin/eosin stainings. Low grade GN was observed
in all groups of B6.Nba2 mice and neither IDO1 deficiency
nor IDO1 enzymatic inhibition significantly affected renal
inflammation (Figure 3A). Similarly, mesangial proliferation
as measured by glomerular size, was unchanged between
the groups of mice (Figure 3B). Secondly, we determined
the presence of IgG, IgM, and complement factor C’3 in
the kidneys by immunofluorescence staining. While there
was no difference in the levels of IgG and IgM deposition
among the groups of B6.Nba2 mice (Figure 3A, red stain;
Figure 3C), we observed significantly increased interstitial-
specific (and reduced glomerular-specific) complement factor
C’3 staining in mice treated with 1-D-MT, regardless of
the presence of IDO1 (p < 0.01; Figure 3A, green stain;
Figure 3D). This pattern was similar to staining results obtained
from age- and sex-matched B6 mice (Figure 3A, bottom
row), suggesting that 1-D-MT treatment dampened renal
complement factor C’3 fixation to glomeruli in an IDO1-
independent manner.
Inhibition of IDO Increases the
T-Dependent Antibody Response to
Exogenous Antigen
Previously IDO has been found to regulate the crosstalk between
T and B cells in the K/BxN mouse model of rheumatoid
arthritis (24). Thus, it was surprising that manipulation of
IDO did not affect ANA levels in B6.Nba2 mice known
to depend on both T and B cells (35, 45). To identify if
IDO is involved in antibody-driven immunity to exogenous
antigen in this model at all, B6.Nba2, B6.Nba2.IDO1−/−,
B6.Nba2 mice treated with 1-D-MT, and B6.Nba2.IDO1−/−
mice treated with 1-D-MT were immunized with the T-
dependent antigen NP-Chicken γ-Globulin (GCC) in Complete
Freund’s Adjuvant (CFA). Mice were immunized on day 0 and
bled every 7 days thereafter to establish if IDO1-deficiency
and/or inhibition of IDO affected the generation of NP-specific
antibodies. As the anti-NP antibody response developed, 1-
D-MT-treated B6.Nba2.IDO1−/− mice displayed significantly
elevated anti-NP specific IgG1 antibodies as compared with all
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FIGURE 3 | 1-D-MT treatment does not affect renal inflammation but reduces complement factor C’3 fixation in kidney glomeruli. Kidneys were harvested from 16
week old IDO1-deficient and -sufficient B6.Nba2 mice treated with PBS or 1-D-MT and from female age-matched B6 control mice. Hematoxylin/eosin staining
showed no significant differences in glomerulonephritis and mesangial proliferation (A,B). Staining for IgG, and IgM showed no measurable differences in glomerular
IgG and IgM brightness levels between B6.Nba2 mice (C and not shown) but a significant increase in interstitial C’3 brightness levels in 1-D-MT treated B6.Nba2
mice (**) (A,D). Each symbol represents one mouse. *p < 0.05; **p < 0.01; Student’s unpaired t-test with Welch’s correction.
other groups of mice (p < 0.05, Figure 4A). Neither IDO1-
deficiency nor 1-D-MT treatment alone, however, had any
effect on the antibody response. To ensure that this increase
was not simply a result of a change in the cytokine balance
and hence class switching properties, we also tested levels of
anti-NP specific total IgG and IgG2b antibodies and found
that all isotypes were similarly elevated in 1-D-MT treated
B6.Nba2.IDO1−/− mice (Figures 4B,C). Thus, IDO1 deficiency
coupled with pharmacologic inhibition of IDO enhanced
the antibody response to exogenous T-dependent antigen in
B6.Nba2 mice.
DISCUSSION
It has been speculated that IDO plays a regulatory role in SLE due
to the identification of elevated IDO activity in SLE patients with
an active type I interferon signature (28). We have previously
reported that type I interferon-induced signaling and type I
interferon-producing pDCs are required for disease development
in B6.Nba2 mice (33, 37), prompting us to investigate the role of
IDO in this model. Corresponding with a previous report in the
MRLlpr/lpr mousemodel of lupus (18), we found elevated levels of
IDO1 and increased total IDO enzymatic activity in spleen tissue
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FIGURE 4 | IDO suppresses antibody responses to an exogenous
T-dependent antigen in B6.Nba2 mice. B6.Nba2 and B6.Nba2.IDO−/− were
left treated or not with 1-D-MT after immunization with 20 µg NP-CGG
conjugate in Complete Freund’s Adjuvant (CFA). (A) The data display the mean
± SEM of anti-NP IgG1 levels in serum obtained from three separate rounds of
immunization; B6.Nba2 (n = 5), B6.Nba2 + 1-D-MT (n = 5),
B6.Nba2.IDO1−/− (n = 5), B6.Nba2.IDO1−/− + 1-D-MT (n = 3). (B,C)
Serum IgG2b and total IgG levels 28 days post immunization. Each symbol
represents one mouse. **p < 0.01. Two-way ANOVA (A) or Student’s unpaired
t-test with Welch’s correction (B,C).
from lupus-prone female B6.Nba2 mice as compared with non-
autoimmune prone female B6 mice. We were unable to detect
IDO2 protein in total spleen samples from either strain.
Expression of IDO1 by spleen cell subsets have previously
been shown in SignR1+ MZM (18, 46) and SigH+ pDCs (22, 23).
Unpublished data from our lab suggest a similar distribution
pattern, although further studies are needed to verify these due
to recently identified non-specific binding patterns by a subset
of IDO1-specific antibodies (47). A functional role for IDO1
expression in these cell subsets, however, has been described.
First, SignR1+ MZM are involved in the control of immune
activation in response to the uptake and clearance of blood
borne antigens via scavenger receptors MARCO, co-expressed
by many but not all SignR1+ MZM, and SignR1 itself (48–
52). In addition, MZM have been suggested to be involved
in the clearance of apoptotic cells and the induction of self-
tolerance (46). Thus, IDO1 expression by this highly specialized
cell subset likely serves to dampen the activation of adaptive
immunity under non-infectious conditions. Interestingly, we
found reduced percentages of SignR1+ MZM in all B6.Nba2
mice as compared with B6 control mice (see Table 1), suggesting
that SignR1+ MZM could play a role in disease pathogenesis
in the B6.Nba2 model. Secondly, pDCs accumulate in B6.Nba2
mice (36) and disease progression can be halted by ablation of
SigH+ pDCs, the latter potentially due to the ensuing reduction
in type I interferon production (37). While expression of IDO1
by pDCs seems counterintuitive, IDO1-expressing SigH+ pDCs
have been shown to play an immunoprotective role in animal
models of multiple sclerosis and atherosclerosis (22, 23). Our
preliminary data similarly suggest elevated IDO1 expression in
SigH+ pDCs in both B6.Nba2 and lupus-prone (NZB x NZW)F1
mice. Whether IDO1 expression by pDCs is induced by IFNγ,
type I interferon or both as previously described (12, 53), and
therefore a secondary readout of heightened disease activity,
remains under investigation.
Complement activation is a well-known indication of lupus-
like renal disease in mouse models of SLE, although the precise
mechanism by which complement is involved remains unclear.
For example, genetic deficiency of DAF, a natural C′3 inhibitor,
in lupus-prone MRLlpr/lpr mice did not affect the severity of
lupus nephritis (54), while overexpression of Crry, another C′3
inhibitor, protected against lupus nephritis in the same model
(55). It is interesting to note, that despite IDO1/total IDO
manipulation having no effect on autoantibody production, IgG-
IC depositions within the kidney glomeruli, and spleen cell
subset activation and accumulation patterns, we still observed
that interstitial complement factor C’3 staining remained high
upon treatment with 1-D-MT, similarly to the pattern observed
in non-autoimmune B6 mice. Correspondingly, C’3 staining
decreased within the glomeruli of 1-D-MT-treated B6.Nba2
mice. There is some evidence that IDO1 and/or IDO2 activity
can affect complement activation in different diseases (56, 57),
however the exact mechanism remains unknown and no study
has specifically investigated the role of IDO on complement in
renal disease. In fact, IDO1 has been found to play different
roles in different renal diseases. In a nephrotoxic serum nephritis
mouse model, IDO enzymatic inhibition using 1-MT (-D or -
L isomer) exacerbated proteinuria and end-stage renal disease
signifying a protective role for IDO (58), although whether this
can be accredited to IDO1 or IDO2 was not determined. In a
separate study, IDO1 expression and function was associated
with inhibition of the GCN2 stress pathway leading to reduced
macrophage inflammation and lower inflammatory cytokine
levels (59). Oppositely, IDO1 was found to play a pathogenic role
following renal ischemia-reperfusion injury, as IDO1 deficiency
or total IDO enzymatic inhibition prevented kidney injury as
determined by serum creatinine levels (60). In this study, the
use of 1-D-MT vs. 1-D/L-MT or 1-L-MT was also not described,
however the similarity of the results obtained from IDO1-KO
mice and 1-MT treated mice, suggest that the effect was mediated
by IDO. Finally, in chronic kidney disease (CKD) patients, total
IDO enzymatic activity correlated with the severity of the disease;
although it was speculated that this association was as a result of
the ongoing inflammation, and thus not a primary, driving factor
of CKD (61). Taken together, it is possible that inhibition of IDO
(−1 or−2) via 1-D-MT treatment affects T cells, properdin levels
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and/or results in reduced levels of inflammatory cytokines by yet
other mechanisms, ultimately leading to diminished macrophage
infiltration and less complement activation.
In summary, we have here shown that B6.Nba2 lupus-prone
mice express elevated levels of IDO1 and increased total IDO
enzymatic activity. Given the elevated levels of IFNα reported in
both B6.Nba2 and (NZB x NZW)F1 mice, it is possible that the
elevated levels of IDO1 protein is due to a direct transcriptional
effect, although future studies manipulating IFNα levels in
B6.Nba2 mice are needed to firmly establish this association.
Surprisingly, IDO1 expression and total IDO enzymatic activity
were largely dispensable for lupus-like disease development in
B6.Nba2 mice, as neither genetic ablation of IDO1 nor chemical
inhibition of total IDO resulted in any consistent statistically
significant changes in serum ANA levels or Nba2-driven splenic
cell subset abnormalities, although significantly less C’3 was co-
localized with IgG-IC within kidney glomeruli of mice treated
with 1-D-MT. Future studies evaluating the effects of more
specific IDO inhibitors on renal tissue are needed to establish if
IDO (-1 and/or−2) inhibition may be beneficial for SLE patients
suffering from glomerulonephritis.
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